Maravai Lifesciences Holdings, Inc. Class A MRVI

SAN DIEGO, September 29, 2026--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expand

Maravai LifeSciences Holdings has seen its share price swing sharply in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$7.65 price supported by the cash flows the business can generate over time, based on a Discounted Cash Flow (DCF) view of its intrinsic value? The stock has delivered a 171.3% return over the past year, which puts real pressure on the question of whether that move is fully backed by the cash the business is...

Maravai LifeSciences Holdings (MRVI) has been drawing attention after recent share price swings, with the stock closing at US$7.37 on 24 September 2026. Investors are weighing mixed return patterns across different holding periods. Recent trading in Maravai LifeSciences Holdings has been choppy, with a 7-day share price return of 7.75% but a 30-day move that is down 12.57%, while the 90-day gain of 20.42% and year to date share price return of 116.76% signal momentum that has cooled recently...

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a

Moby summary of Maravai LifeSciences Holdings, Inc.'s Q2 2026 earnings call

SAN DIEGO, August 06, 2026--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates.

SAN DIEGO, July 22, 2026--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

SAN DIEGO, July 20, 2026--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical compon

JUPITER, Fla., June 16, 2026--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 7, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) affirmed a strong start to the year, driven by strong demand in the core TriLink base business and strength in the higher-margin portfolio. Increased focus on cost structure and […]

Price target work on Maravai LifeSciences Holdings has shifted, with updated modeling lifting the estimated fair value per share from US$4.33 to US$5.70. Analysts are tying this move to refreshed assumptions that reflect recent Q4 results and new guidance, while still showing a split between more bullish and more cautious views on the stock. As you read on, you will see how these changing targets fit into the broader story and how to track the evolving analyst narrative over time. Analyst...